Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
Level 3 - non-randomized controlled study
Retrospective comparative cohort study evaluating tumor pathology and clinical outcomes across defined hereditary and non-hereditary groups
OpenAlex W2068588019 · doi:10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w
What was done
Researchers evaluated clinicopathologic characteristics and survival outcomes across three groups: BRCA1-related hereditary breast cancer (HBC; 26 families, 90 pathology cases), "Other" HBC enriched for BRCA2 based on linkage to chromosomes 17q/13q or family history features (26 families, 85 cases), and non-HBC controls (187 cases). Tumors were assessed for histologic type, grade, ploidy, and S-phase fraction by quantitative DNA flow cytometry, alongside clinical stage and follow-up data.
What was found
BRCA1-related and Other HBC presented at a significantly earlier mean age (42.8 and 47.1 years vs. 62.9 years, P = 0.0001) and lower stage (P = 0.003) than non-HBC. Compared with non-HBC, invasive BRCA1-related tumors had lower diploidy rates (13% vs. 35%, P = 0.002), lower mean aneuploid DNA index (1.53 vs. 1.73, P = 0.002), higher mitotic grade 3 rates (OR = 4.42, P = 0.001), and higher aneuploid mean S-phase fraction (16.5% vs. 9.3%, P < 0.0001). Other HBC patients had more tubular-lobular group carcinomas (OR = 2.56, P = 0.007). BRCA1-related patients experienced significantly fewer recurrences than Other HBC patients (P = 0.013) and showed crude survival comparable to breast cancer patients at large.
Why it matters
This study provides early evidence that BRCA1-linked breast cancers harbor distinctive, aggressive biological features—notably marked aneuploidy and high proliferation rates—yet paradoxically do not confer worse recurrence or survival outcomes compared to other hereditary cases.
Limits
Classification was primarily based on genetic linkage and family history rather than direct germline mutation sequencing. Follow-up data were limited to available clinical records, and the "Other HBC" group was heterogeneous with only a subset definitively linked to BRCA2.
Cited by
- supports Studying male breast cancer cases aided in the identification of BRCA genes due to the rarity of breast cancer in men.